Cantor Fitzgerald Predicts SPRY FY2026 Earnings

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Free Report) - Stock analysts at Cantor Fitzgerald issued their FY2026 earnings per share estimates for ARS Pharmaceuticals in a research report issued to clients and investors on Monday, June 9th. Cantor Fitzgerald analyst J. Schimmer anticipates that the company will earn ($0.45) per share for the year. The consensus estimate for ARS Pharmaceuticals' current full-year earnings is ($0.55) per share.

ARS Pharmaceuticals (NASDAQ:SPRY - Get Free Report) last released its quarterly earnings results on Wednesday, May 14th. The company reported ($0.35) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.35). The firm had revenue of $7.97 million for the quarter, compared to the consensus estimate of $7.48 million.

Several other research firms have also recently weighed in on SPRY. William Blair reissued an "outperform" rating on shares of ARS Pharmaceuticals in a research report on Monday, March 3rd. Scotiabank assumed coverage on shares of ARS Pharmaceuticals in a research note on Friday, March 7th. They issued a "sector outperform" rating and a $30.00 target price on the stock. Finally, Wall Street Zen lowered ARS Pharmaceuticals from a "hold" rating to a "sell" rating in a report on Thursday, May 22nd. One research analyst has rated the stock with a sell rating, five have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, ARS Pharmaceuticals has a consensus rating of "Moderate Buy" and an average target price of $31.00.

ARS Pharmaceuticals Stock Performance

Shares of ARS Pharmaceuticals stock traded up $0.99 during mid-day trading on Tuesday, hitting $15.39. 1,170,862 shares of the stock were exchanged, compared to its average volume of 1,290,654. The company has a market capitalization of $1.51 billion, a P/E ratio of -30.18 and a beta of 0.84. The company has a 50-day simple moving average of $14.15 and a 200 day simple moving average of $12.85. ARS Pharmaceuticals has a 12 month low of $7.55 and a 12 month high of $18.51.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the company. Bernard Wealth Management Corp. bought a new stake in ARS Pharmaceuticals during the fourth quarter valued at $27,000. ANTIPODES PARTNERS Ltd bought a new stake in shares of ARS Pharmaceuticals during the 1st quarter valued at about $37,000. PNC Financial Services Group Inc. boosted its position in shares of ARS Pharmaceuticals by 78,100.0% during the 1st quarter. PNC Financial Services Group Inc. now owns 3,910 shares of the company's stock valued at $49,000 after acquiring an additional 3,905 shares during the last quarter. KLP Kapitalforvaltning AS purchased a new position in shares of ARS Pharmaceuticals during the fourth quarter worth about $73,000. Finally, BNP Paribas Financial Markets bought a new position in shares of ARS Pharmaceuticals in the fourth quarter worth approximately $75,000. 68.16% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other ARS Pharmaceuticals news, insider Eric Karas sold 10,000 shares of the firm's stock in a transaction dated Thursday, March 20th. The stock was sold at an average price of $14.00, for a total value of $140,000.00. Following the completion of the transaction, the insider now owns 7,696 shares in the company, valued at $107,744. This trade represents a 56.51% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Laura Shawver sold 50,002 shares of the stock in a transaction dated Monday, April 7th. The stock was sold at an average price of $12.30, for a total transaction of $615,024.60. Following the completion of the sale, the director now directly owns 210,346 shares in the company, valued at approximately $2,587,255.80. The trade was a 19.21% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 332,971 shares of company stock valued at $4,621,888. Company insiders own 33.50% of the company's stock.

ARS Pharmaceuticals Company Profile

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.